IMVT vs VRDN
IMVT: Immunovant is a clinical-stage biotechnology company developing FcRn-inhibiting therapies to treat patients suffering from debilitating IgG-mediated autoimmune diseases. VRDN: A biopharmaceutical company commercializing therapies for thyroid eye disease and developing a pipeline of treatments for autoimmune and rare diseases.
Side-by-side fundamentals
| Metric | IMVT | VRDN | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $44.37 | $24.29 | |
| Market cap as of 2026-08-24 | $9.2B | $2.8B | |
| Net margin as of 2026-08-24 | n/a | -544.1% | |
| Gross margin as of 2026-08-24 | n/a | +2.4% | |
| Operating margin as of 2026-08-24 | n/a | -569.7% | |
| ROE as of 2026-08-24 | -69.6% | -61.4% | VRDN higher |
| ROA as of 2026-08-24 | -62.5% | -46.0% | VRDN higher |
| Debt / equity as of 2026-08-24 | 0.00 | 0.54 | IMVT lower |
| Revenue CAGR (3y) SEC XBRL | n/a | -2.5% | |
| Beta as of 2026-08-24 | 0.83 | 1.10 | |
| 1-year return as of 2026-08-21 close | +199.0% | +34.8% | IMVT higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.